Coty Inc. (COTY) Analysts See $0.24 EPS; Sophiris Bio (SPHS) Has 0.64 Sentiment

January 17, 2018 - By Nellie Frank

Analysts expect Coty Inc. (NYSE:COTY) to report $0.24 EPS on February, 8.They anticipate $0.06 EPS change or 20.00% from last quarter’s $0.3 EPS. COTY’s profit would be $179.88M giving it 21.48 P/E if the $0.24 EPS is correct. After having $0.10 EPS previously, Coty Inc.’s analysts see 140.00% EPS growth. The stock increased 1.08% or $0.22 during the last trading session, reaching $20.62. About 98,652 shares traded. Coty Inc. (NYSE:COTY) has declined 25.39% since January 17, 2017 and is downtrending. It has underperformed by 42.09% the S&P500.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $67.09 million. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

The stock decreased 1.85% or $0.0421 during the last trading session, reaching $2.2279. About 54,867 shares traded. Sophiris Bio, Inc. (SPHS) has risen 192.94% since January 17, 2017 and is uptrending. It has outperformed by 176.24% the S&P500.

Sabby Management Llc holds 0.05% of its portfolio in Sophiris Bio, Inc. for 333,641 shares. Palo Alto Investors Llc owns 247,000 shares or 0.02% of their US portfolio. Moreover, B & T Capital Management Dba Alpha Capital Management has 0.01% invested in the company for 10,128 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 210 shares.

Analysts await Sophiris Bio, Inc. (NASDAQ:SPHS) to report earnings on March, 26. They expect $-0.11 earnings per share, down 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.11 actual earnings per share reported by Sophiris Bio, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.17 in Q3 2017. Its up 0.03, from 1.14 in 2017Q2. It is positive, as 36 investors sold Coty Inc. shares while 91 reduced holdings. 39 funds opened positions while 110 raised stakes. 510.97 million shares or 5.68% more from 483.48 million shares in 2017Q2 were reported. Ameriprise Fin invested in 1.11 million shares. Amalgamated Bank reported 53,672 shares. Peak6 Ltd Partnership holds 0% or 36,886 shares. Northwestern Mutual Wealth Mngmt invested in 375 shares. Public Employees Retirement Association Of Colorado reported 68,336 shares or 0.01% of all its holdings. Ruffer Llp holds 50,000 shares or 0.04% of its portfolio. Wellington Mgmt Gru Ltd Liability Partnership invested 0.15% in Coty Inc. (NYSE:COTY). 33,056 are owned by Qs Invsts Ltd Liability. Putnam Invests Limited Liability Company reported 3.21M shares. 202,432 are owned by Pub Employees Retirement Sys Of Ohio. Cannell Peter B & accumulated 504,930 shares. Aviva Public Limited Company owns 298,886 shares or 0.03% of their US portfolio. Rampart Invest Mgmt Communication Limited Company holds 5,971 shares or 0.03% of its portfolio. Fifth Third Bank & Trust reported 0% stake. Mitsubishi Ufj Tru And Bk Corp stated it has 952,570 shares.

Since August 24, 2017, it had 1 buying transaction, and 0 sales for $42.38 million activity. 2.60 million Coty Inc. (NYSE:COTY) shares with value of $42.38 million were bought by JAB Cosmetics B.V..

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts